Skip to main contentSkip to contextural navigationSkip to main navigationIf you are having problems using this page with a screen reader follow this link for a more compatible version
University of Plymouth home page
home |  Help |  contact us |  sitemap |  search  University Logo

Kim Tieu

 

Personal photograph uploaded by Kim Tieu

Dr Kim Tieu - ()

  • Job title: Associate Professor (Reader) in Clinical Neurobiology, Centre for Biomedical Research - Translational & Stratified Medicine (Peninsula Schools of Medicine and Dentistry)
  • Address: R2RL25, The John Bull Building, Tamar Science Park, Research Way,
    Plymouth, Devon, PL6 8BU
  • Telephone: +441752432053
  • Email: kim.tieu@plymouth.ac.uk


Role

 

2013-present   Principal Investigator,  Associate Professor (Reader), Department of Clinical Neurobiology, Plymouth University Peninsula Schools of Medicine and Dentistry.

2013-present    Adjunct Faculty, University of Rochester (Rochester, New York).

 

Qualifications & background

2004-2012      Principal Investigator ( Assistant Professor)    Departments of Environmental Medicine and Neurology in the Center for Translational Neuromedicine, University of Rochester (Rochester, New York).

 

2000-2004       Post-doctoral fellow     Department of Neurology, Columbia University, New York, New York.

1995-2000       Ph.D                             Neuroscience, Department of Neuropsychiatry, University of Saskatchewan, Canada.

1993-2000       Pharmacist                  Saskatchewan, Canada

1988-1993       B.S.P.                          Pharmacy, College of Pharmacy,

                                                            University of Saskatchewan, Canada.

 



Research interests

My research interest has always been to study mechanisms of neuronal dysfunction and degeneration as seen in Parkinson’s disease (PD), with the ultimate goal of developing effective therapies for this devastating neurological disorder.  Our research projects address the following fundamental questions: 1) Is mitochondrial dysfunction pathogenic in PD?  If so, can mitochondrial dynamics be targeted for PD treatment?  2) Glial-neuronal interactions: How do glial cells contribute to the vulnerability of dopamine neurons (the primary cell type affected in PD)?  3) Gene-environment interactions: Do mutations linked to PD render dopamine neurons more susceptible to environmental insults?  To address these questions, we perform rigorous biochemical, histological, functional and genetic analyses in experimental models of PD.  When applicable, post-mortem human samples are also used.

 

UoP Research group membership

Clinical Neuroscience 
VOYAGE: Biomedical solutions